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Objectives. This study sought to determine whether pravastatin
affects clinical or angiographic restenosis after coronary balloon
angioplasty.
Background. Experimental data and preliminary clinical stud-
ies suggest that lipid-lowering drugs might have a beneficial effect
on restenosis after coronary angioplasty.
Methods. In a multicenter, randomized, double-blind trial, 695
patients were randomized to receive pravastatin (40 mg/day) or
placebo for 6 months after successful balloon angioplasty. All
patients received aspirin (100 mg/day). The primary angiographic
end point was minimal lumen diameter (MLD) at follow-up,
assessed by quantitative coronary angiography. A sample size of
313 patients per group was required to demonstrate a difference of
0.13 mm in MLD between groups (allowing for a two-tailed alpha
error of 0.05 and a beta error of 0.20). To allow for incomplete
angiographic follow-up (estimated lost to follow-up rate of 10%),
690 randomized patients were required. Secondary end points
were angiographic restenosis rate (restenosis assessed as a cate-
goric variable, >50% stenosis) and clinical events (death, myo-
cardial infarction, target vessel revascularization).
Results. At baseline, clinical, demographic, angiographic and
lipid variables did not differ significantly between groups. In
patients treated with pravastatin, there was a significant reduc-
tion in total and low density lipoprotein cholesterol and triglyc-
eride levels and a significant increase in high density lipoprotein
cholesterol levels. At follow-up the MLD (mean 6 SD) was 1.47 6
0.62 mm in the placebo group and 1.54 6 0.66 mm in the
pravastatin group (p 5 0.21). Similarly, late loss and net gain did
not differ significantly between groups. The restenosis rate (re-
currence >50% stenosis) was 43.8% in the placebo group and
39.2% in the pravastatin group (p 5 0.26). Clinical restenosis did
not differ significantly between groups.
Conclusions. Although pravastatin has documented efficacy in
reducing clinical events and angiographic disease progression in
patients with coronary atherosclerosis, this study shows that it
has no effect on angiographic outcome at the target site 6 months
after coronary angioplasty.
(J Am Coll Cardiol 1997;30:863–9)
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Over the past 15 years, it has becoming increasingly evident
that percutaneous transluminal coronary angioplasty (PTCA)
is an effective method of myocardial revascularization. Com-
pared with medical treatment in patients with left anterior
descending coronary artery stenosis, PTCA has demonstrated
its superiority in terms of decreasing symptoms and improving
exercise performance (1). Six multicenter randomized trials
comparing PTCA with coronary artery bypass graft surgery
(CABG) have shown that survival without myocardial infarc-
tion was similar for the two treatment modalities (2–9).
However, patients treated by PTCA had more revasculariza-
tion procedures than patients treated by CABG, mainly related
to the occurrence of restenosis. This phenomenon remains the
Achilles’ heel of PTCA. Restenosis is relatively frequent,
occurring in 35% to 40% of dilated lesions, is often associated
with recurrence of symptoms requiring further revasculariza-
tion and has a major economic impact. The mechanisms of
restenosis have been extensively studied, and four major
mechanisms have been identified: immediate recoil, incorpo-
ration of thrombus and a healing process in response to
arterial injury that involves myointimal proliferation and vas-
cular remodeling.
When the present study was designed, myointimal prolifer-
ation was considered to play a dominant role in the pathogen-
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esis of restenosis. Furthermore, several lines of evidence
suggested that the phenomenon of restenosis and that of
atherosclerosis progression had some pathophysiologic char-
acteristics in common. Several angiographic studies had de-
scribed less progression and even some regression of athero-
sclerosis when lipid levels were lowered (10,11). In addition,
experimental and clinical data showed a trend toward a lower
restenosis rate when patients undergoing PTCA received fish
oil supplementation (12–17). In this context, the Pre´vention
des Restenoses par Elisor apre`s Dilatation Coronaire Trans-
luminale (Prevention of Restenosis by Elisor After Translumi-
nal Coronary Angioplasty [PREDICT]) study* was designed to
determine whether treatment with pravastatin, an HMG coen-
zyme A reductase inhibitor, was able to reduce restenosis after
PTCA.
Methods
Study design. From 1992 to 1994, 695 patients were en-
rolled in this prospective multicenter, randomized, double-
blind, placebo-controlled trial. The protocol was approved by
the ethics committee of the University of Lille. The last
angiographic follow-up procedure was performed in December
1994. Twenty-nine French centers (see Appendix) participated
in the study.
Patients 25 to 75 years old, with a left ventricular ejection
fraction, assessed by angiography, that exceeded 40% were
eligible for inclusion. In addition, all patients were required to
have total cholesterol levels between 200 and 310 mg/dl and
triglyceride levels ,500 mg/dl. Patients with a recent myocar-
dial infarction (within 15 days) and patients who had previ-
ously undergone PTCA or CABG of the target vessel were
excluded. Patients were also excluded if they received drugs
not allowed by protocol (fish oil or other lipid-lowering agents
within 1 month of the procedure), corticosteroids or immuno-
suppressive drugs.
Patients were recruited from those who had undergone
successful, uncomplicated PTCA of one or more coronary
stenoses in the participating institutions. Randomization was
performed after PTCA and within 24 h of the procedure. After
giving written informed consent, patients were randomly as-
signed to receive either pravastatin (40 mg/day) or placebo. All
patients received aspirin (100 mg/day).
Two months after the procedure, patients returned for
outpatient assessment and blood sampling for lipid measure-
ments. At 6-month follow-up, lipid measurements and coro-
nary angiography were performed. Follow-up angiography was
performed earlier if there was a clinical indication. If follow-up
angiography performed ,4 months did not demonstrate re-
stenosis, the patient was encouraged to return for further
angiography at 6 months.
Lipid measurements. The following measurements were
performed at baseline and at 2 and 6 months: total, low density
lipoprotein (LDL), high density lipoprotein (HDL) and HDL
subfraction E (HDL-E) cholesterol; triglycerides; lipopro-
tein(a) [Lp(a)]; lipoprotein E-B; and apolipoprotein A1 and B.
All lipid measurements were performed at a core labora-
tory (Service d’Etude et de Recherche sur les Lipoproteines et
l’Atherosclerose [SERLIA], J. C. Fruchart, PhD, Institut Pas-
teur, Lille, Director). The technicians performing the measure-
ments were unaware of the treatment allocation.
Angiographic measurements. Catheterization and PTCA
were performed according to standard techniques. Isosorbide
dinitrate (2 mg) was injected into the coronary artery before
each angiogram in an attempt to standardize vasomotor tone.
The angiograms were recorded on standard 35-mm film. Three
views of the stenosis were obtained at the time of PTCA and
were recorded on a worksheet to allow them to be duplicated
exactly at the time of follow-up angiography. An attempt was
made to obtain two orthogonal views for each lesion.
At the end of the study, films were sent to the core labora-
tory at the University of Lille (J. M. Lablanche, MD and
E. McFadden, Directors) for qualitative and quantitative anal-
ysis. Angiographic analysis was performed without knowledge
of treatment allocation or of clinical data. Quantitative analysis
was performed on sequential angiograms filmed in the same
projection. The frames were selected by the cardiologist who
performed the quantitative analysis from the projection in
which the stenosis appeared most severe just before angio-
plasty. Quantitative analysis was performed with the Computer-
Assisted Evaluation of Stenosis and Restenosis (CAESAR)
system, a computerized automatic analysis system that has
been described in detail elsewhere (18). Briefly, the 35-mm
cine film was projected with a 35AX projector (Tagarno,
Denmark), and the cine frame selected for analysis was
scanned with a high resolution video camera. The signal
produced by the video camera was digitized and displayed on
a video monitor. Regions of interest were chosen in the vessel,
and a centerline was manually traced with use of a light pencil.
The contours of the vessel were then automatically detected on
the basis of the weighted sum of first- and second-derivative
functions applied to the digitized brightness information. The
diameter of the empty coronary catheter was used to convert
the imaging data from pixels to millimeters. The mean diam-*Elisor is the registered trade name of Pravastatin.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CARE 5 Cholesterol and Recurrent Events (trial)
CAESAR 5 Computer-Assisted Evaluation of Stenosis and
Restenosis system
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
LRT 5 Lovastatin Restenosis Trial
MLD 5 minimal lumen diameter
PREDICT 5 Prevention of Restenosis by Elisor After Transluminal
Coronary Angioplasty (trial)
PTCA 5 percutaneous transluminal coronary angioplasty
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eters of proximal and distal reference segments and the
minimal diameter of the stenotic segment were measured. The
accuracy (defined as the signed difference between the mea-
sured and the true value) and the precision (defined as the
standard deviation of these differences) of the CAESAR
system were previously determined in a study analyzing cine
films of Plexiglas blocks containing precision-drilled models of
coronary arteries filled with contrast medium. The accuracy
was 0.07 mm and the precision 0.14 mm. To assess the
intraobserver and interobserver variability of the system, 90
arterial segments from patients undergoing PTCA were ana-
lyzed by two independent observers (J.M.L., E.P.M.) and
reanalyzed at a remote time. The mean intraobserver varia-
tion, expressed as the standard deviation of the differences, was
0.10 mm, and the interobserver variation was 0.11 mm.
End points. Predetermined clinical and angiographic end
points were assessed. The primary angiographic end points
were minimal lumen diameter (MLD) at follow-up angiogra-
phy, net gain and late loss in MLD at the dilated site. When
more than one lesion was dilated in the same patient, the first
lesion dilated was used for assessment of the primary angio-
graphic end point. Secondary end points were the percent of
patients with recurrence .50% stenosis at follow-up (at any
dilated lesion) and the following clinical end points: occur-
rence of death, nonfatal target lesion myocardial infarction,
CABG or repeat PTCA of the target lesion. Target lesion
myocardial infarction was defined clinically at the participating
site. These clinical end points constitute clinical restenosis.
Definitions. Acute gain was defined as the MLD at the
dilated site immediately after PTCA minus the MLD just
before the procedure. Late loss was defined as the MLD at the
dilated site immediately after the procedure minus the MLD at
the dilated site 6 months after PTCA. Net gain was defined as
the MLD at the dilated site 6 months after angioplasty minus
the MLD at the dilated site just before angioplasty. Angio-
graphic results given at follow-up are those obtained at 6
months, or earlier in case of early restenosis.
Data management and statistical analysis. The study ad-
hered to the European Guidelines for Good Clinical Research
Practice. Data were prospectively recorded by the investigators
at each site on case record forms and were monitored by
clinical research associates before data entry. The forms were
verified by range and consistency checks, with queries returned
to the investigators for any missing or inconsistent data.
Clinical safety of the study drugs was evaluated, and adverse
events occurring during the study were recorded in the case
record form. At each center, research assistants monitored
patient compliance with assigned therapy.
Statistical analysis was performed with use of SAS PC
software (Version 6.04, SAS Institute). All tests were two-
tailed, and p values ,0.05 were considered significant. The
predetermined primary end point of the study was the MLD at
the dilated site 6 months after angioplasty. For this end point,
it was calculated that a sample size of 313 patients/group was
required to demonstrate a difference of 0.13 mm in MLD
between the groups (allowing for a two-tailed alpha error of
0.05 and a beta error of 0.20). To allow for incomplete
angiographic follow-up (estimated lost-to-follow-up rate of
10%), it was decided to randomize 690 patients. Two groups
were defined: 1) all randomized patients (intention to treat
group); 2) patients who had a follow-up angiogram that could
be analyzed by the continuous MLD approach (per-protocol
group) and who met angiographic criteria.
Baseline characteristics were compared in the two groups
using the t test, chi-square test or Fischer exact test, as
appropriate. Clinical events occurring during follow-up were
compared with the Mantel-Haenszel test on ordered catego-
ries. When more than one clinical event occurred per patient,
the most severe event was used for the analysis with the
following decreasing order of severity: death, nonfatal myocar-
dial infarction, CABG and target vessel repeat PTCA. MLD
and changes in MLD and percent diameter stenosis (immedi-
ate gain, late loss and net gain) were compared between groups
by t tests. Two-way analysis of variance was performed to test
changes in lipid variables. Continuous variables are expressed
as mean value 6 SD.
Results
Patients. In total, 695 patients were randomized and make
up the intention to treat cohort; 347 were assigned to prava-
statin therapy and 348 to placebo. Because of adverse events (1
patient) and withdrawal of consent, 661 patients were seen at
the 2-month follow-up visit. During subsequent follow-up, five
patients had adverse events and stopped the treatment. Sev-
enteen patients were lost to follow-up, and 14 refused the
angiographic follow-up. In total, 625 patients (90% of the study
group) had angiographic follow-up.
Taking into account patients excluded by the core labora-
tory (significant [.50%] residual stenosis after PTCA) or
those unsuitable for quantitative analysis (n 5 69), 556 patients
(283 in the placebo group, 273 in the pravastatin group) were
available for the per-protocol angiographic analysis. On aver-
age, the patients underwent follow-up angiography 184 6 52
days after the procedure. There was no significant difference
between the two groups (184 6 55 days in the placebo group,
183 6 47 days in the pravastatin group, p 5 0.83).
Baseline clinical and angiographic characteristics. The
two groups were well matched in terms of baseline clinical
characteristics (Table 1). Mean age and the distribution of risk
factors for coronary disease did not differ significantly between
groups. The proportion of patients with a history of myocardial
infarction was similar in both groups. A similar proportion of
patients in both groups had stable angina or unstable angina
(defined as severe chest pain at rest with electrocardiographic
changes) or were asymptomatic.
The anatomic distribution and qualitative angiographic
characteristics of the target lesions (assessed by the American
College of Cardiology/American Heart Association classifica-
tion) did not differ significantly between groups (Table 2).
Lipid measurements. At baseline, the mean cholesterol
level was 231 6 36 mg/dl in the placebo group and 228 6
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38 mg/dl in the pravastatin group (p 5 0.42). The mean level of
LDL cholesterol was 157 6 29 mg/dl in the placebo group and
155 6 32 mg/dl in the pravastatin group (p 5 0.3); mean HDL
cholesterol was 47 6 12 mg/dl in the placebo group and 47 6
13 mg/dl in the pravastatin group (p 5 0.8) (Table 3).
During the study there were no significant changes in lipid
variables in the placebo group. In contrast, there was a
significant decrease in mean total cholesterol in the pravastatin
group after 2 and 6 months of treatment compared with the
mean baseline value. Mean LDL cholesterol was also signifi-
cantly lower at 2 and 6 months than at baseline. There was a
significant increase in HDL cholesterol at 2 and 6 months
compared with baseline values (Table 3). Apolipoprotein A1
significantly increased in the pravastatin group, whereas apo-
lipoprotein B significantly decreased. Lp(a) levels were slightly
but not significantly greater at 6 month follow-up (Table 4).
Angiographic results. The major results of the quantitative
angiographic analysis are presented in Table 5. There were no
significant differences at baseline in reference diameter or in
MLD between groups. The MLD was 0.84 6 0.28 mm in the
placebo group and 0.82 6 0.29 mm in the pravastatin group
(p 5 0.37).
At follow-up, the MLD, which was the primary angio-
graphic end point, was 1.47 6 0.62 mm in the placebo group
and 1.54 6 0.66 mm in the pravastatin group (p 5 0.21). The
cumulative distribution curves for MLD are shown in Figure 1.
The late loss in MLD was similar in both groups (0.48 6
0.56 mm in the placebo group, 0.46 6 0.58 mm in the
pravastatin group, p 5 0.54), as was the net gain (0.62 6
0.59 mm in the placebo group, 0.71 6 0.62 mm in the
pravastatin group, p 5 0.07).
A secondary angiographic end point was percent stenosis.
At baseline, mean stenosis severity at the PTCA site was
similar (72 6 8.8%) in the pravastatin and placebo groups
(71.1 6 8.1%, p 5 0.11). After PTCA, mean residual stenosis
was 33 6 8.5% in the placebo group and 33 6 8.5% in the
pravastatin group (p 5 0.49). At angiographic restudy, there
was no significant difference between the two groups, with
mean stenosis severity 49.7 6 20% in the placebo group and
48.4 6 20% in the pravastatin group (p 5 0.44). Furthermore,
the proportion of patients with recurrence of significant
(.50%) stenosis did not differ significantly (p 5 0.26) between
groups (43.8% in the placebo group, 39.2% in the pravastatin
group).
Clinical restenosis. The analysis, based on the intention to
treat cohort, included 695 patients (348 in the placebo group,
347 in the pravastatin group). There were four deaths in the
pravastatin group: two sudden deaths plus one related to
myocardial infarction and one related to a cerebrovascular
accident. One sudden death occurred in the placebo group.
The mortality rate did not differ significantly between groups
(p 5 0.21).
Four nonfatal myocardial infarctions occurred in each
group. Target vessel revascularization during follow-up was
performed in 75 patients (21.6%) receiving placebo and 66
(19%) treated with pravastatin. Thus, there was no overall
difference in clinical restenosis between the groups (Table 6).
Relation between lipid measurements and angiographic
restenosis. There was no relation between late loss in MLD
and changes in lipid variables associated with pravastatin
treatment.
Discussion
The present study was designed to determine whether
treatment with pravastatin could reduce angiographic resten-
osis after coronary balloon angioplasty. Angiographic resten-
osis was assessed using both a continuous approach (analysis of
MLD) and a categoric approach (recurrence of significant
[.50%] stenosis after initially successful PTCA). Both analy-
ses demonstrated conclusively that pravastatin had no signifi-
cant effect on angiographic restenosis.
Present study: clinical and angiographic outcome. Prava-
statin treatment was associated with a significant reduction in
total and LDL cholesterol and with a slight but significant
increase in HDL cholesterol. However, pravastatin treatment
had no significant effect on either angiographic restenosis or
rate of clinical events after PTCA. The incidence of death,
Table 1. Baseline Clinical Characteristics
Placebo Group
(n 5 348)
Pravastatin
Group (n 5 347)
p
Value
Mean age (yr) 58.5 58.2 NS
Range 32–75 31–75
Male 289 (83%) 293 (84.4%) 0.61
Smoker 118 (34%) 116 (30.5%) 0.89
Hypertension 108 (31%) 105 (30.3%) 0.82
Diabetes 30 (8.6%) 20 (5.8%) 0.14
PVD 20 (5.7%) 13 (3.7%) 0.21
Hx of stroke 7 (2%) 6 (1.7%) 0.78
Previous MI 131 (37.6%) 127 (36.6%) 0.77
Stable angina 140 (40.2%) 142 (40.9%) 0.85
Unstable angina 62 (17.8%) 49 (14.1%) 0.18
Data presented are number (%) of patients, unless otherwise indicated.
Hx 5 history; MI 5 myocardial infarction; PVD 5 peripheral vascular disease.
Table 2. Baseline Lesion Characteristics
Placebo Group
(n 5 308)
Pravastatin
Group (n 5 299)
p
Value
Lesion location
RCA 92 (29.9%) 90 (30.1%) 0.95
LAD 126 (40.9%) 108 (36.1%) 0.22
LCx 90 (29.2%) 101 (33.8%) 0.22
Lesion type*
A 159 (51.6%) 159 (53.2%) 0.70
B1 103 (33.4%) 107 (35.8%) 0.35
B2 44 (14.3%) 31 (10.3%) 0.14
C 2 (0.7%) 2 (0.7%) 0.97
*American College of Cardiology/American Heart Association/class-
ification. Data presented are number (%) of patients. LAD 5 left anterior
descending coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right
coronary artery.
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nonfatal myocardial infarction or target lesion revasculariza-
tion was similar in both groups. The calculations of sample size
were based on the number of patients required to demonstrate,
with adequate power, an effect of treatment on angiographic
restenosis after PTCA; a much larger sample size, as well as a
longer period of follow-up, would be required to assess a
potential effect on clinical outcome. Pravastatin did not reduce
clinical restenosis in the present trial, but this finding is not at
variance with the results of previous studies.
Statins and progression of atherosclerosis: previous stud-
ies. Previous studies that examined the effects of the statins on
the occurrence of clinical events in patients with coronary
atherosclerosis demonstrated a reduction in clinical events in
patients receiving statin therapy. This benefit was observed in
different populations and with different molecules, notably in
the Scandinavian Simvastatin Survival Study (4-S) (19), the
West of Scotland Coronary Prevention Study (WOSCOPS)
(20) and the CARE study (21). In the 4S study, the actuarial
survival curves diverged only after 12 months and in the CARE
study after 2 years.
Several angiographic trials have found that lipid-lowering
drugs were able to limit progression and even to induce
regression of atherosclerotic lesions. This was demonstrated in
the Regression Growth Evaluation Statin Study (REGRESS)
study (11) that compared pravastatin with placebo over a
longer time period. This question was not addressed in the
PREDICT trial, which was designed to assess the effect of
pravastatin on restenosis and not its effects on progression or
regression in nondilated segments.
Lipid-lowering therapy: effects on restenosis. Previous
studies that examined the effects of lipid-lowering drugs on
restenosis have produced conflicting results. A potential ben-
Table 3. Lipid Variables
Placebo
Group
(mean 6 SD)
No. of
Pts
Pravastatin
Group
(mean 6 SD)
No. of
Pts
p
Value
TC (mg/dl)
Baseline 231 6 36 347 228 6 38 341 0.42
2 mo 247 6 38 315 196 6 34 320 0.0001
6 mo 239 6 40 285 195 6 37 288 0.0001
LDL-C (mg/dl)
Baseline 157 6 29 343 155 6 32 338 0.3
2 mo 164 6 33 311 119 6 29 312 0.0001
6 mo 159 6 33 283 119 6 31 284 0.0001
HDL-C (mg/dl)
Baseline 47 6 12 345 47 6 13 341 0.8
2 mo 51 6 15 313 54 6 13 317 0.001
6 mo 49 6 14 286 52 6 13 288 0.01
TG
Baseline 139 6 67 346 140 6 75 341 0.8
2 mo 149 6 91 315 126 6 81 320 0.001
6 mo 159 6 125 285 134 6 88 288 0.01
HDL-C 5 high density lipoprotein cholesterol; LDL-C 5 low density lipoprotein cholesterol; Pts 5 patients; TC 5
total cholesterol; TG 5 triglycerides.
Table 4. Lipoprotein Variables
Placebo
Group
(mean 6 SD)
No. of
Pts
Pravastatin
Group
(mean 6 SD)
No. of
Pts
p
Value
Apo A1 (mg/dl)
Baseline 130.9 6 25.7 347 133.5 6 25.2 343 0.2
2 mo 146.4 6 24.1 314 153.2 6 25.7 320 0.006
6 mo 143.8 6 27.6 282 150.5 6 26.9 286 0.003
Apo B (mg/dl)
Baseline 132.8 6 25.7 348 131.1 6 28.2 343 0.4
2 mo 148.1 6 32.1 314 113.5 6 29.1 320 0.0001
6 mo 143.1 6 34.5 282 113.5 6 32.4 286 0.0001
Lp(a) (mg/dl)
Baseline 27.6 6 33.6 346 27.2 6 32.2 340 0.86
2 mo 28.6 6 34.7 311 31.5 6 38.3 315 0.33
6 mo 26.5 6 30.6 276 32.1 6 38.8 279 0.06
Apo 5 apolipoprotein; Lp 5 lipoprotein; Pts 5 patients.
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eficial effect of the statins on the occurrence of restenosis was
suggested by a relatively small study (22) that included 157
patients who received lovastatin or conventional care. That
study (22), which was neither blinded nor randomized, re-
ported that the rate of restenosis was 12% with lovastatin
compared with 44% with conventional care; however, angio-
graphic follow-up was incomplete. Subsequently, a small ran-
domized trial (23) with pravastatin in a Japanese population
demonstrated no effect on angiographic restenosis.
A large randomized trial, the Lovastatin Restenosis Trial
(LRT) (24), examined the effect of lovastatin on restenosis.
This well conducted and well designed study showed that
treatment with a relatively high dose of lovastatin had no effect
on the occurrence of restenosis at 6 months after PTCA. The
results of the present study are similar to the results of the
LRT. There were two methodologic differences between the
studies, namely, the fact that in the LRT treatment was begun
between 7 and 10 days before angioplasty, and the dose of
statin used was higher (40 mg of lovastatin orally twice daily)
compared with 40 mg/day of pravastatin in the present study.
The population studied was somewhat larger in the PREDICT
study (695 patients) than in in the LRT (404 patients). The
reference diameters in the dilated vessels were slightly smaller
in the LRT than in the PREDICT study, but the conclusions
concerning the continuous and categoric variables were essen-
tially the same. No trials to date have dealt with the effects of
simvastatin or fluvastatin, statins that have been shown in vitro
to have smooth muscle cell migration inhibitory properties on
restenosis.
Other recent studies (25–27) have demonstrated a lack of
association between serum lipid levels and restenosis and the
lack of effect of lipid-lowering agents or fish oil supplementa-
tion on restenosis.
Conclusions. The results of the present study, together
with those of the other studies discussed, demonstrate that
despite its positive effects on the angiographic and ultrasound
progression of atherosclerosis, pravastatin has no effect on
Figure 1. Cumulative distribution curves for MLD be-
fore and immediately after angioplasty and at follow-up
(FU). The curves that are superimposed before angio-
plasty shift to the right after the procedure, reflecting the
acute gain in MLD associated with the procedure. At
follow-up, the curves shift back to the left because of the
late loss in MLD during follow-up. The curves for
pravastatin and placebo are essentially superimposed at
all three timepoints, demonstrating the lack of effect of
pravastatin.
Table 5. Angiographic Results
Placebo
Group
(n 5 283)
Pravastatin
Group
(n 5 273)
p
Value
Ref diam (mm)
Before PTCA 3.04 6 0.50 3.06 6 0.45 0.65
After PTCA 3.04 6 0.50 3.06 6 0.45 0.63
At follow-up 3.04 6 0.50 3.05 6 0.45 0.82
MLD (mm)
Before PTCA 0.84 6 0.28 0.82 6 0.29 0.37
After PTCA 1.95 6 0.37 1.99 6 0.39 0.18
At follow-up 1.47 6 0.62 1.54 6 0.66 0.21
Changes in MLD (mm)
Acute gain 1.10 6 0.34 1.17 6 0.39 0.04
Late loss 0.48 6 0.56 0.46 6 0.58 0.54
Net gain 0.62 6 0.59 0.71 6 0.62 0.07
% stenosis
Before PTCA 71.1 6 8.1 72.2 6 8.8 0.11
After PTCA 33.3 6 8.56 32.8 6 8.5 0.49
At follow-up 49.7 6 19.8 48.4 6 20 0.44
Data presented are mean value 6 SD. MLD 5 minimal lumen diameter;
PTCA 5 percutaneous transluminal coronary angioplasty; Ref diam 5 reference
diameter.
Table 6. Clinical Events During Follow-Up
Placebo
Group
(n 5 348)
Pravastatin
Group
(n 5 347)
p
Value
Death 1 (0.3%) 4 (1.15%) 0.21
Acute MI 4 (1.1%) 4 (1.15%) 1.0
CABG 18 (5.2%) 15 (4.3%) 0.72
Repeat target lesion PTCA 57 (16.4%) 51 (14.7%) 0.54
Total 80 (23%) 74 (21.3%)
Data presented are number (%) of patients. CABG 5 coronary artery bypass
graft surgery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty.
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angiographic or clinical restenosis 6 months after coronary
angioplasty despite a significant reduction in total and LDL
cholesterol. These results should not be interpreted to mean
that statin therapy is of no benefit in patients undergoing
angioplasty. Although treatment with statins appears to have
no effect on restenosis, their effect on the progression of
atherosclerosis and on the clinical events associated with such
progression now appears to have been established beyond
reasonable doubt. Owing to the contrasting effects of lipid
lowering on atherosclerosis and restenosis, it seems unlikely
that restenosis and the progression of atherosclerosis have a
similar pathophysiologic basis. Current evidence suggests that
restenosis is related to an exaggerated healing process com-
bined with vascular remodeling.
Appendix
Participating Centers and Principal Investigators for
the PREDICT Trial*
Clinique St. Martin, Caen (83): P. Commeau; Centre Hospitalier Universitaire
(CHU), Caen (72): G. Grollier; CHU, Besanc¸on (61): J. P. Bassand; CHU,
Grenoble (49): J. Machecourt; CHU, Clermont-Ferrand (48): J. Cassagnes; CHU,
Strasbourg (38): J. M. Mossard; CHU Necker, Paris (35): A. Vacheron, J. P.
Metzger; CHU, Creteil (31): A. Castaigne; CHU, Nancy (30): N. Danchin; CHU,
Broussais, Paris (27): J. L. Guermonprez, S. Makowski; CHU, Lille (26): M.
Bertrand, C. Bauters; CHU, Brest (24): J. Boschat; CHU Ambroise Pare´, Paris
(21): J. P. Bourdarias; Centre Hospitalier Re´gional, Mulhouse (20): J. P.
Monassier; CHU, Amiens (19): J. C. Quiret; CHU, Tours (16): P. Raynaud;
Institut Arnaut Tzanck, Nice (15): R. Schmitt; CHU, Nantes (15): D. Crochet;
CHU, Rennes (13): J. C. Pony, H. Le Breton; CHU Timone, Marseille (11): M.
Bory; CHU, Pitie´ Salpe´trie`re, Paris (11): G. Drobinski; CHU, Rouen (9): B. Letac;
CHU Bichat, Paris (8): M. C. Aumont, D. Himbert; CHU, Angers (6): P. Geslin;
CHU, Dijon (3): J. E. Wolf; CHU Purpan, Toulouse (3): P. Bernadet; CHU,
Bordeaux (2): P. Besse; Clinique Volney, Rennes (2): P. Descaves; CHU Tenon,
Paris (1): A. Vahanian.
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